← All trials
NCT05159947
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Jan 31, 2022
- Completion date
- Jan 31, 2024
- First posted
- Dec 16, 2021
- Last posted
- Dec 16, 2021
- Enrollment
- 1112
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Xiamen UniversityCollaborator
- Xuzhou Medical UniversityCollaborator
- Inner Mongolia Medical UniversityCollaborator
- Huazhong University of Science and TechnologyReponsible party - principal investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Tianjin Medical UniversityCollaborator
- Qingdao UniversityCollaborator
- Qingdao Central HospitalCollaborator
- Hainan People's HospitalCollaborator
- Jingzhou Central HospitalCollaborator
- Central South UniversityCollaborator
- Guangzhou Red Cross HospitalCollaborator
- Shanghai Xuhui District Central HospitalCollaborator
- Neijiang Second People's HospitalCollaborator
- Weihai Municipal HospitalCollaborator
- Inner Mongolia Baogang HospitalCollaborator
- Jinlin UniversityCollaborator
- Xiangtan Central HospitalCollaborator
- jining medical collegeCollaborator
- Beijing Haijinge medicine Science-tech CO.Collaborator
- Changjiang Shipping General HospitalCollaborator
- People's Hospital Of YichangCollaborator
- Daqing Oil Field HospitalCollaborator
- Daqing people's HospitalCollaborator
- Dezhou People's Hospital,ShandongCollaborator
- Wuhan Central HospitalCollaborator
- Wuhan NO. 4 hospitalCollaborator
- Xi’an Gaoxin HospitalCollaborator
- Xiang Yang NO.1 People's HospitalCollaborator
- Xuancheng people's hospitalCollaborator
- Yan'an University Affiliated HospitalCollaborator
- Qujing first people's HospitalCollaborator
- Enshi Tujia and Miao Autonomous Prefecture Central HospitalCollaborator
- Zhangzhou Municipal Hospital of Fujian ProvinceCollaborator
- Fukuang General Hospital of Liaoning health industry groupCollaborator
- Hengshui People's HospitalCollaborator
- Huanggang Central HospitalCollaborator
- Sinopharm Dongfeng General HospitalCollaborator
- Qiqihar Medical CollegeCollaborator
- Jiaxing Maternity and Child Health Care HospitalCollaborator
- Linfen Central HospitalCollaborator
- Nanyang nanshai hospitalCollaborator
- Harbin Medical UniversityCollaborator
- Wuhan UniversityCollaborator
- Government of ChinaCollaborator
- Inner Mongolia University of Science and TechnologyCollaborator
- Nanhua UniversityCollaborator
- Nanyang Medical CollegeCollaborator
- Shihezi University Medical CollegeCollaborator
- Suzhou Huyun New Drug Research and Development Co., LtdCollaborator
- Taizhou Hospital of Zhejiang ProvinceCollaborator
- Tai'an Central HospitalCollaborator
- Tancheng first people's HospitalCollaborator
- Deyang People's HospitalCollaborator
- Meihekou Central HospitalCollaborator
- Hebei UniversityCollaborator
- Jiangsu Taizhou People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.